

PRODUCT INFORMATION

AiRuiKa;Carbarizumab;Carrizumab;HR-301210;HR301210;INCSHR-1210;INCSHR1210;SHR 1210;HSR1210;HSR-1210 **Common Name**

PE-conjugated Conjugate

PD1;PD-1;CD279;SLEB2;hPD-1;hPD-l;hSLE1 Svnonvms

Applications Flow Cyt Recommended Dilutions Flow Cyt 1:100

Formulation & Reconstitution

Liquid
☐PBS with 0.05% Proclin300, 1% BSA

IgG type IgG4 Reactivity Human PD-1 Target 015116 **Uniprot ID**

Description PE-conjugated Anti-PD-1(camrelizumab biosimilar) mAb

Delivery **Under Development**

Storage & Shipping Store at 2°C-8°C for 6 months

Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Background

Usage Research use only

All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Email: info@dimabio.com Website: www.dimabio.com

DIMA Disclaimer

